What the evidence shows
The short version
Transcutaneous vagus nerve stimulation has been studied across several conditions, some more thoroughly than others. The strongest evidence is in drug-resistant epilepsy, with a growing body of work in depression, migraine, and stroke rehabilitation. It is a real treatment with real effects and a good safety record. It is not a miracle. This page tells you what the best studies actually found, in language we would use if you were sitting at our kitchen table.
If you want the full clinical literature with references, study designs, and quality-of-evidence ratings, the clinicians zone has it.
Open the clinician evidence library
How we think about evidence
Before we get into numbers, a word on how to read them.
A study can be impressive and still not mean what you think it means. A small pilot trial with an unblinded design can report large improvements and still be too fragile to build a treatment decision on. A big randomised trial can report a modest effect and still be the most important piece of evidence in the field, because the effect is real and reproducible.
Our approach is to lean on the bigger, better-controlled studies, to be honest about where the evidence is thinner, and to never claim more than the data supports. If you see a bold promise in a brochure for any medical device, ask for the study. If you cannot find it, be careful.
Epilepsy: the strongest case
The most rigorous evidence for tVNS is in drug-resistant epilepsy. This is the population for whom medication has not brought seizures fully under control, and who face a choice between adding more drugs, considering surgery, or trying something else.
- In the largest randomised controlled trial to date, published in 2023, just under 45% of people using tVNS achieved at least a 50% reduction in the number of their seizures, compared with around 17% in the control group.
- A real-world study following patients for one to two years at Beijing Tiantan Hospital reported that over 60% achieved at least a 50% reduction with longer-term use.
- Five-year outcome studies suggest that the responder rate for tVNS sits at around 30%, which is broadly comparable to the 32% reported for implanted vagus nerve stimulators in similar populations.
- The benefit tends to build slowly. Most studies show the clearest signal at around twenty weeks of daily use.
What this means in practice. If you have drug-resistant epilepsy and you use tVNS consistently as prescribed, there is a meaningful chance your seizures will become less frequent. There is also a real chance they will not. The research is clearer than the marketing, and we prefer to quote the research.
Depression
Vagus nerve stimulation has been used as a treatment for depression for decades, originally in its invasive form. The long-term response rates reported for invasive VNS sit around 67%, which is higher than conventional drug therapy in treatment-resistant populations.
Transcutaneous stimulation is younger as a treatment for depression, with smaller trials and more variability between studies. The mechanism is plausible. The early evidence is encouraging. But we would not frame tVNS as a first-line treatment for depression, and we would expect any clinician prescribing it to do so alongside the rest of a considered care plan, not instead of one.
Migraine
For chronic migraine, the picture is mixed but promising. A different, neck-based device, transcutaneous cervical vagus nerve stimulation (gammaCore, not the auricular ear device we distribute), has regulatory clearance for migraine and cluster headache in several regions. In the best cluster-headache study (PREVA), adding it to standard care gave about 3.9 fewer attacks per week than standard care alone (a between-group difference; active fell by 5.9 attacks per week and the control group by 2.1).
For tVNS through the ear specifically, the trial data on migraine is smaller but points in the same direction. The mechanism is consistent: vagal afferents modulate pain processing in the brainstem and descending inhibitory pathways that matter for headache.
Other indications
Research into tVNS has extended into a number of other areas. Most of this work is earlier stage than the epilepsy and depression literature, but two themes are worth noting.
- Stroke rehabilitation. A meta-analysis of eighteen randomised trials involving 954 patients found meaningful improvements in upper limb motor function and in swallowing function after stroke. The evidence quality was rated moderate to high for some outcomes.
- Gastrointestinal function. Systematic reviews of functional dyspepsia and related conditions report improvements in symptoms, quality of life, and mood, consistent with the vagus nerve's role in the brain-gut axis.
These are not primary indications for the tVNS device we distribute, but they explain why the research community is paying attention. The vagus nerve reaches a lot of places, and stimulating it has consequences that extend beyond any single condition.
Safety
The common side effects are mild and local: tingling or redness where the electrode sits, occasional headache, and occasional dizziness in the first few sessions. In almost every case, these settle with use or with small adjustments to fit and intensity. The Instructions for Use list the fuller range of possible effects, and note that some people may experience a temporary increase in seizures (in epilepsy) or low mood (in depression) early in treatment. Serious side effects are uncommon, but tVNS should be used under medical supervision and any concerns reported to your clinician.
There are a few contraindications. Per the Instructions for Use, tVNS should not be used by people who are pregnant, who have an active implant (such as a cochlear implant, an implanted vagus nerve stimulator, or a cardiac pacemaker), who have a cerebral shunt, or who have sore, broken, or diseased skin where the electrode sits. Anyone with a heart rhythm problem should check with their doctor first. It is intended for adults aged 18 and over. Your clinician will check these before recommending the device.
What the evidence does not say
We think it is important to be equally clear about what the research does not show.
- It does not show that tVNS works for everyone. Response rates in the best studies sit at under half of participants, even in the populations where the evidence is strongest.
- It does not show a quick fix. The benefit usually takes weeks to months to appear, and consistency of use matters.
- It does not replace your existing treatment. tVNS is an adjunct, used alongside the medication, therapy, or lifestyle interventions your clinician has already put in place.
- It does not show identical results across every sub-group. Some patient profiles respond better than others. This is why we prefer an honest conversation up front to an oversimplified promise.
What to do next
If you have read this far and you are thinking about whether tVNS could fit into your care, here are the sensible next steps.
- Read the condition page that applies to you. They go into more detail on what to expect, who is and is not a good candidate, and the practical side of daily use.
- Talk to your clinician. We are always happy to talk to them too. Sometimes that helps.
- Contact us with any questions. We will give you a straight answer, including whether we think tVNS is unlikely to help in your situation.
Contact Anatomical Concepts UK
This page is for information only. It is not medical advice. Any decision about tVNS should be made with your clinician, who knows your full medical history.
tVNS is a Class IIa medical device manufactured by tVNS Technologies GmbH, Germany. Distributed in the UK by Anatomical Concepts UK Ltd.